Nystatin (Fungicidin): Polyene Antifungal Agent for Candida and Aspergillus Research

Executive Summary: Nystatin (Fungicidin) is a polyene antifungal antibiotic with potent activity against multiple Candida species, including C. albicans, C. glabrata, and C. krusei (APExBIO product page). Its mechanism involves binding to ergosterol in fungal cell membranes, causing membrane disruption and cell death. In vitro, Nystatin exhibits MIC₉₀ values around 4 mg/L for C. albicans and inhibits adhesion of non-albicans Candida to human epithelial cells. Liposomal Nystatin protects neutropenic mice from Aspergillus fumigatus infection at doses as low as 2 mg/kg/day. Nystatin is highly soluble in DMSO, enabling reliable formulation for antifungal assays (see extended analysis).

Biological Rationale

Nystatin (Fungicidin) is part of the polyene class of antifungal agents. It is effective against a broad range of fungal pathogens, especially yeast forms such as Candida spp. and Aspergillus spp. The clinical and laboratory need for Nystatin arises from increasing antifungal resistance among non-albicans Candida strains and the demand for reliable agents in drug screening and mechanistic research (related article—this article provides updated benchmarks for resistance profiles). Nystatin is not absorbed through the gastrointestinal tract, limiting its systemic toxicity and making it suitable for topical, oral, and laboratory applications. Its established MIC benchmarks and robust solubility in DMSO make it a preferred control in antifungal susceptibility testing.

Mechanism of Action of Nystatin (Fungicidin)

Nystatin exerts its antifungal effect by binding to ergosterol, a key component of fungal cell membranes. This interaction forms pores in the membrane, causing leakage of intracellular ions and metabolites. The resulting loss of membrane integrity leads to cell lysis and fungal death. Nystatin's action is highly specific to fungi, as mammalian cells contain cholesterol instead of ergosterol. Contrary to some caveolae-mediated endocytosis inhibitors, Nystatin does not disrupt clathrin-mediated endocytosis or macropinocytosis in Drosophila S2 cells challenged with Spiroplasma eriocheiris (Wei et al., 2019), confirming its selectivity for ergosterol over cholesterol.

Evidence & Benchmarks

• Nystatin demonstrates MIC₉₀ values of approximately 4 mg/L for Candida albicans in standardized in vitro testing (APExBIO).
• Effective inhibitory concentrations for various Candida species range from 0.39 to 3.12 μg/mL under laboratory conditions (RPMI 1640, 35°C, 24–48 h) (source).
• Nystatin significantly reduces adhesion of Candida species to human buccal epithelial cells, with non-albicans species more affected than C. albicans (protocol reference).
• Liposomal Nystatin at 2 mg/kg/day prevents dissemination and mortality in neutropenic mice infected with Aspergillus fumigatus (APExBIO).
• Nystatin is highly soluble in DMSO at ≥30.45 mg/mL, but insoluble in ethanol and water; stock preparation requires warming to 37°C or sonication for optimal dissolution (practical guidance).
• Nystatin does not inhibit Spiroplasma eriocheiris entry into Drosophila S2 cells, supporting its specificity for ergosterol-containing membranes (Wei et al., 2019).

Applications, Limits & Misconceptions

Nystatin (Fungicidin) is used primarily as a research reagent for: (1) antifungal drug screening, (2) cell viability and cytotoxicity assays, (3) model system studies of Candida and Aspergillus infection, and (4) mechanistic studies of fungal membrane biology (further protocol optimization—this article expands on workflow integration strategies).

While it is effective in vitro and in animal models, Nystatin is not suitable for systemic human therapy due to poor absorption and potential for toxicity at high concentrations. It does not affect bacteria or non-ergosterol-containing cells and is not an inhibitor of all endocytic pathways. Nystatin is for research use only and not for clinical or diagnostic applications.

Common Pitfalls or Misconceptions

• Nystatin does not inhibit bacterial or mycoplasma infection via the caveola-mediated pathway. Its lack of effect on Spiroplasma eriocheiris entry into S2 cells confirms this specificity (Wei et al., 2019).
• Nystatin is insoluble in water and ethanol. Stock solutions must be prepared in DMSO and may require warming or sonication for full dissolution (product documentation).
• It is not suitable for systemic administration in humans. Oral or topical use is standard; systemic delivery is limited by toxicity and poor absorption.
• Nystatin's inhibitory effect on C. albicans adhesion is less pronounced than on non-albicans species. Protocols for adhesion assays must account for this variability (see lab troubleshooting).
• Nystatin should not be used as a substitute for cholesterol-disrupting agents when modeling endocytosis in non-fungal systems.

Workflow Integration & Parameters

For laboratory use, Nystatin (Fungicidin) from APExBIO (SKU B1993) should be dissolved in DMSO at ≥30.45 mg/mL. Warming to 37°C and/or sonication enhances solubility. Stock solutions can be stored at -20°C for several months without degradation. Recommended working concentrations for antifungal assays are typically 0.39–4 μg/mL for Candida species, adjusted according to strain susceptibility and assay type. For in vivo models, liposomal Nystatin at 2 mg/kg/day is effective against Aspergillus infection in neutropenic mice. Always confirm batch identity and solubility prior to use. For extended antifungal assay guidance, see this scenario-driven analysis (this article addresses experimental reproducibility in contrast to the present mechanistic overview).

Conclusion & Outlook

Nystatin (Fungicidin) is a well-characterized polyene antifungal with proven selectivity, potency, and utility in research. Its DMSO solubility, defined MIC benchmarks, and validated animal model efficacy make it an essential tool for antifungal screening and mechanistic studies. APExBIO's B1993 formulation ensures batch consistency and reproducibility. As resistance patterns shift among fungal pathogens, Nystatin remains a reference standard for Candida and Aspergillus models. Future work may focus on formulation innovations and combinatorial screening with emerging antifungal agents.